Skip to main content
SpringerLink
Log in

Statistical Analysis in Pharmacoeconomic Studies

A Review of Current Issues and Standards

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

The increasing number of economic evaluations of healthcare interventions, and of drug therapies in particular, has been well documented. However, surveys have demonstrated that standards of conduct of such studies have not similarly increased. Of particular concern is the lack of development or even consideration of statistical techniques in the reporting of studies. This article addresses issues that must be considered both in the conduct and in the assessment of the quality of studies. Throughout the paper, examples of pharmacoeconomic analyses are used to illustrate the points made.

Recommendations for the conduct of future pharmacoeconomic studies are given. Such recommendations specifically relate to the level of testing that is conducted, the choice of statistical tests and the manner in which statistical significance is reported. In addition, existing methods for the statistical analysis of cost-effectiveness ratios and for the determination of sample size in economic evaluations are discussed, and a partial solution to this issue is offered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Backhouse ME, Backhouse RJ, Edey SA. Economic evaluation bibliography. Health Econ 1993; 1 Suppl.

  2. Elixhauser A, Luce BR, Taylor WR, et al. Health care CBA/ CEA: an update on the growth and composition of the literature. Med Care 1993; 31 (7 Suppl.): JS1–JS11

    Article  PubMed  CAS  Google Scholar 

  3. Coyle D, Drummond M. Does expenditure on pharmaceuticals give good value for money? Current evidence and policy implications. Health Policy 1993; 26: 55–75

    Article  PubMed  CAS  Google Scholar 

  4. Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee [including submissions involving economic analyses]. Canberra: Department of Health, Housing and Community Services, 1992

    Google Scholar 

  5. Ontario Ministry of Health. Ontario Guidelines for economic analyses of pharmaceutical products. Toronto: Ministry of Health, 1994

    Google Scholar 

  6. Drummond MF. Guidelines for pharmacoeconomic studies: the way forward. PharmacoEconomics 1994; 6: 493–497

    Article  PubMed  CAS  Google Scholar 

  7. McGhan WF, Lewis NJW. Guidelines for pharmacoeconomic studies. Clin Ther 1992; 14: 486–494

    PubMed  CAS  Google Scholar 

  8. Adams ME, McCall NT, Gray DT, et al. Economic analysis in randomized control trials. Med Care 1992; 30: 231–243

    Article  PubMed  CAS  Google Scholar 

  9. Udvarhelyi IS, Colditz GA, Rae AB, et al. Cost-effectiveness and cost-benefit analyses in the medical literature: are the methods being used correctly? Ann Intern Med 1992; 116: 238–244

    PubMed  CAS  Google Scholar 

  10. O’Brien BJ, Drummond MF, Labelle RJ, et al. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994; 32: 150–163

    Article  PubMed  Google Scholar 

  11. Briggs AH, Sculpher MJ, Buxton MJ. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1993; 3: 95–104

    Article  Google Scholar 

  12. Keeler E. Decision trees and Markov models in cost-effectiveness research. In: Sloan FA, editor. Valuing health care: cost, benefits and effectiveness of pharmaceuticals and other medical technologies. Cambridge: Cambridge University Press, 1995: 185–205

    Chapter  Google Scholar 

  13. Steinberg EP, Topol EJ, Sakin JW, et al. Cost and procedure implications of thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 1988; 12: 58A–68A

    Article  PubMed  CAS  Google Scholar 

  14. Tsevat J, Durand-Zaleski I, Paucker SG. Cost-effectiveness of antibiotic prophylaxis for dental procedures in patients with artificial joints. Am J Public Health 1989; 79: 739–743

    Article  PubMed  CAS  Google Scholar 

  15. Castellano AR, Nettleman MD. Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia. JAMA 1991; 266: 820–824

    Article  PubMed  CAS  Google Scholar 

  16. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation. Med Decis Making 1985; 5: 157–177

    Article  PubMed  CAS  Google Scholar 

  17. Gabriel SE, Campion ME, O’Fallon WM. Acost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994; 37 (3): 333–341

    Article  PubMed  CAS  Google Scholar 

  18. Chalfin DB, Holbein ME, Fein AM, et al. Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients. JAMA 1993; 269 (2): 249–255

    Article  PubMed  CAS  Google Scholar 

  19. Schneider T, Fagnani F, Lanoe JL, et al. Economic analysis of an immunosuppressive strategy in renal transplantation. Health Policy 1988; 9: 75–89

    Article  PubMed  CAS  Google Scholar 

  20. Jaakkimainen L, Goodwin PJ, Pater J, et al. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol 1990; 8: 1301–1309

    PubMed  CAS  Google Scholar 

  21. Goodwin PJ, Feld R, Evans WK, et al. Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol 1988; 6: 1537–1547

    PubMed  CAS  Google Scholar 

  22. Vermeer F, Simoons ML, de Zwaan C, et al. Cost benefit analysis of early thrombolytic treatment with intracoronary streptokinase: twelve months follow up report of the randomised multicentre trial conducted by the Interuniversity Cardiology Institute of the Netherlands. Br Heart J 1988 May; 59 (5): 527–534

    Article  PubMed  CAS  Google Scholar 

  23. Tubman TRJ, Halliday HL, Normand C. Costs of surfactant replacement treatment for severe neonatal respiratory distress syndrome: a randomised controlled trial. BMJ 1990; 301: 842–845

    Article  PubMed  CAS  Google Scholar 

  24. Fenton FR, Tessier L, Contandriopoulos AP, et al. A comparative trial of home and hospital psychiatric treatment: financial costs. Can J Psychiatry 1982; 27 (3): 177–187

    PubMed  CAS  Google Scholar 

  25. Thompson MS, Read JL, Hutchings C, et al. The cost-effectiveness of auranofin: results of a randomized clinical trial. J Rheumatol 1988; 15: 33–42

    Google Scholar 

  26. van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and C/E ratios alongside a clinical trial. Health Econ 1994; 3: 309–319

    Article  PubMed  Google Scholar 

  27. O’Brien BJ, Drummond MF. Statistical versus quantitative significance in the socioeconomic evaluation of medicines. Phar-macoEconomics 1994; 5 (5): 389–398

    Google Scholar 

  28. Scitovsky AA, Cline MW, Abrams DI. Effects of the use of AZT on the medical care costs of persons with AIDS in the first 12 months. J Acquir Immune Defic Syndr 1990; 3: 904–912

    PubMed  CAS  Google Scholar 

  29. Drummond MF, Menzin J, Oster G. Methodological issues in economic assessments of new therapies: the case of colony-stimulating factors. PharmacoEconomics 1994; 6 Suppl. 2: 18–26

    Article  PubMed  Google Scholar 

  30. Rutten-van Molken MPMH, van Doorslaer EKA, van Vliet RCJA. Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Econ 1994; 3: 333–345

    Article  Google Scholar 

  31. Chapekis AT, Burek K, Topol EJ. The cost:benefit ratio of acute intervention for acute myocardial infarction: results of a prospective, matched pair analysis. Am Heart J 1989; 118: 878–882

    Article  PubMed  CAS  Google Scholar 

  32. Johannesson M. The impact of age on the cost-effectiveness of hypertension treatment - an analysis of randomised drug trials. Med Decis Making 1994; 14 (3): 236–244

    Article  PubMed  CAS  Google Scholar 

  33. Gardner MJ, Altman DG. Statistics with confidence — confidence intervals and statistical guidelines. London: British Medical Journal, 1989

    Google Scholar 

  34. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146 (4): 473–481

    CAS  Google Scholar 

  35. Detsky AS. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. PharmacoEconomics 1993; 3: 354–361

    Article  PubMed  CAS  Google Scholar 

  36. O’Brien B, Willan A. Cost-effectiveness ratios in clinical trials: from deterministic to stochastic models [abstract]. Proceedings of the American Statistical Association. Toronto: American Statistical Association, 1994: 127

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Department of Epidemiology and Community Medicine, University of Ottawa, and the Clinical Epidemiology Unit, Department of Research, F6, Ottawa Civic Hospital, 1053 Carling Avenue, Ottawa, Ontario, K1Y 4E9, Canada

    Douglas Coyle

Authors
  1. Douglas Coyle
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coyle, D. Statistical Analysis in Pharmacoeconomic Studies. Pharmacoeconomics 9, 506–516 (1996). https://doi.org/10.2165/00019053-199609060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199609060-00005

Keywords

Search

Navigation